<DOC>
	<DOCNO>NCT01093534</DOCNO>
	<brief_summary>The purpose see solifenacin effect bladder wall thickness urine inflammatory marker measurement 12 week treatment .</brief_summary>
	<brief_title>Study 2 Doses Solifenacin Succinate Female Subjects With Overactive Bladder .</brief_title>
	<detailed_description>Participants satisfy selection criterion end 2-week , single blind , placebo run-in period randomize receive 12-week double-blind treatment solifenacin 5 mg 10 mg daily , placebo .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Symptoms overactive bladder ( OAB ) , include urinary frequency , urgency urge incontinence , great equal 3 month Urodynamic diagnosis detrusor overactivity ( DO ) Either na√Øve antimuscarinic treatment ( i.e . prior history use antimuscarinic agent ) 6months antimuscarinic treatment free ( i.e . antimuscarinic treatment within 6 month ) prior screen visit Bladder postvoid residual volume le 30 ml Available complete study History stress urinary incontinence , urethral sphincter incompetence neurogenic detrusor overactivity History , sign symptom suggestive urinary tract infection ( confirm positive urine analysis ) , obstruction urogenital prolapse ( great grade II ) History urinary tract operation within 6 month prior screen Indwelling catheter permanent catheter fit History pelvic area radiotherapy treatment Uncontrolled diabetes mellitus History fibromyalgia Postpartum breastfeeding within 3 month prior screen visit Either pregnant intend become pregnant study sexually active , childbearing potential unwilling utilize reliable method birth control ( note : reliable method contraceptive pill combination type , hormonal implant injectable contraceptive ) Positive prestudy hepatitis B surface antigen , hepatitis C antibody human immunodeficiency virus ( HIV ) result time screen History drug / alcohol abuse time screen History urinary retention , severe gastrointestinal obstruction ( include paralytic ileus intestinal atony toxic megacolon severe ulcerative colitis ) , myasthenia gravis , uncontrolled narrow angle glaucoma shallow anterior chamber deem risk condition Undergoing hemodialysis severe renal impairment moderate hepatic impairment treatment potent cytochrome p450 ( CYP ) 3A4 inhibitor , e.g . Ketoconazole Currently dose medication ( ) intend treat overactive bladder symptom history nondrug treatment , electrical therapy , magnetic field stimulation , pelvic floor treatment bladder training intend treat overactive bladder symptom within 6 month prior screen , described list prohibit medication Currently receive history treatment alpha blocker , botulinum toxin ( cosmetic use acceptable ) , resiniferatoxin pelvic floor muscle relaxant within 9 month prior screen Participated clinical study less equal 3 month prior screen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Vesicare</keyword>
	<keyword>Solifenacin</keyword>
	<keyword>Detrusor Overactivity</keyword>
	<keyword>Urinary Nerve Growth Factor</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Bladder wall thickness</keyword>
</DOC>